IL1RL1 and cancer: While there is now ample evidence that the IL33-MC axis is important for many cancers, the multitude of cell types in the TME able to respond to IL33 and mediated either pro- or anti-tumorigenic effects presents a formidable challenge for predicting the outcome of anti-IL33/anti-ST2 therapies.